# Moderna, Inc. (MRNA) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/MRNA
## Company Profile
- Ticker: MRNA
- Exchange: NASDAQ
- Sector: mRNA
- Location: Cambridge, Massachusetts
- Tags: Biologics, Biopharma, Vaccines, mRNA Vaccines, Novel Therapies, Gene Therapy, Rare Disease Gene Therapy, Large Molecule Drugs, Nucleic Acid Drugs, Oncology, Rare Disease, Infectious Disease
## Stock Data
- Close: 61.82 USD
- Market cap: 27088597901.93 USD
- Last updated: 2026-07-17
## Business Overview
Moderna is an mRNA medicines company that built its platform around vaccine science and is now broadening into infectious disease, oncology, and other therapeutic areas. Investors watch how the company converts platform credibility into a wider commercial story.
## Why The Stock Is Moving

MRNA is trading with a steady catalyst profile while investors wait for the next headline that changes the story.

## Geographic Base

Headquartered in Cambridge, Massachusetts and listed on NASDAQ, Moderna is followed within the RNA therapeutics universe for its exposure to platform expansion and vaccine demand cycles.

## Business Model

Moderna follows a platform-led model where product development, regulatory milestones, and demand trends all shape the narrative. The market watches whether the company can convert platform science into broader commercial durability.

## Landscape Position

Compared with more diversified peers, Moderna sits in a higher-catalyst corner of the landscape, where each platform update can move expectations quickly.

## Recent News
- 2026-07-20 10:59 EST — [Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA](https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-build-the-most-powerful-ai-factory-in-life-sciences-with-eb3e7bda) — Source: BMYBristol-Myers Squibb Company
- 2026-07-20 07:00 EST — [European Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds](https://biopharmsignal.com/news/GSK/european-medicines-agency-accepts-submission-to-update-bexsero-label-for-1-dose--8906d096) — Source: GSK plc
- 2026-07-17 09:00 EST — [GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)](https://biopharmsignal.com/news/GSK/gsk-provides-an-update-on-calm-1-and-calm-2-phase-iii-trials-for-camlipixant-in--0e112206) — Source: GSK plc
- 2026-07-16 12:31 EST — [Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia](https://biopharmsignal.com/news/MRK/merck-s-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibit-1b899588) — Source: Merck
- 2026-07-16 12:00 EST — [Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/ALNY/alnylam-to-webcast-conference-call-discussing-second-quarter-2026-financial-resu-458d7635) — Source: Alnylam Pharmaceuticals, Inc.